A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined with Induction in Acute Leukemias who Exhibit in vitro Kinase Inhibitor sensitivity

Principal Investigator

Stephen Spurgeon

Study Purpose

The purpose of this research study is to test the safety of adding a targeted study drug after receiving induction for AML or ALL. The pathways responsible for activating the growth of leukemia cells can be unique to each patient and can change during the course of the disease. The lab test developed by the investigators at OHSU will help screen your blood or bone marrow to find out if your cancer may be sensitive to a specific study drug. This is called “targeted therapy”. The reason for doing this research study is to see if the new investigational screening lab test can help provide individualized treatment for patients with leukemia. This study will allow the researchers to learn more about how AML and ALL responds to treatment.

Medical Condition(s)

Newly diagnosed acute myeloid leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).

Eligibility Criteria

Newly diagnosed acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and physician recommendation based on study inclusion and exclusion criteria.

Age Range

21 - No Upper Age Limit

Healthy Volunteers Needed


Duration of Participation

Treatment period of 1 month. Follow-up for 1 year.

Minors Included



Tara Macey, PhD


Stephen Spurgeon, MD

Recruitment End


Compensation Provided


Go Back